BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Genetown

  Cambridge’s Semma Therapeutics Lands $114M for Novel Diabetes Quest

  The round was co-led by Eight Roads Ventures and Cowen Healthcare Investments.

  November 30, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Bayer Head of Discovery Exits as Drugmaker Combines Pharma R&D Unit

  The company’s head of Development, Joerg Moeller, is taking the reins of the company’s new R&D program.

  November 30, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  9 Biotechs Facing FDA Decisions in December

  As 2017 comes to a close, 40 drugs have been approved so far, with the record being in 2015, when 46 drugs were approved.

  November 30, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Mettler-Toledo to Begin Layoffs in March, 69 Employees Affected

  Mettler-Toledo will begin to issue pink slips in March to employees at an upstate New York manufacturing facility.

  November 30, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Bay

  3 Big Pharmas That Could be Winners for Investors in the Long Run

  Big pharma stocks have been longtime favorites among investors for several reasons.

  November 30, 2017

   · 

  1 min read
• Gilead Launches Hepatitis C Treatment in China at 20% of U.S. Price

  Gilead priced its Sovaldi treatment for hepatitis C at $8,938 in China - about one-fifth the current price in the U.S.

  November 30, 2017

   · 

  1 min read
• NeoPhore Scientific Founders Publish Breakthrough Immuno-Oncology Discoveries in Nature

  Clinical and now lab data suggest that many cancers with defective DNA repair appear to be highly sensitive to immune surveillance, including when the immune system is modified with agents that disrupt immune “checkpoints”.

  November 30, 2017

   · 

  2 min read
• 

  Drug Development

  Higher Death Rate Forces Bayer to Stop Xofigo/Zytiga Combo Late-Stage Study Early

  An IDMC told Bayer that it should unblind its Phase III clinical trial in prostate cancer in order to further analyze an increased number of fractures and deaths.

  November 30, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  FDA

  Foundation Medicine Wins Approval From the FDA and Medicare for First-of-Its-Kind Cancer Test

  Foundation Medicine’s sequencing diagnostics test for solid tumors that can detect cancer-causing mutations in 324 genes was approved by the FDA Thursday.

  November 30, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Sexual Harassment Scandals Hit Novartis and Pfizer’s Korea Units

  On Wednesday, KBR reported that a male employee at Novartis Korea reported to the company that his female boss sexually harassed him in September.

  November 30, 2017

   · 

  2 min read

   · 

  Alex Keown